Cytokines

Correspondence on ‘Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study’
Aimilios Kaklamanos, Panagiotis Karamichalos, Panayiotis G Vlachoyiannopoulos, Athanasios G Tzioufas

Annals of the Rheumatic Diseases Apr 2021, annrheumdis-2021-220411; DOI: 10.1136/annrheumdis-2021-220411
Anti-inflammatory therapy for COVID-19 infection: the case for colchicine
Aaron Z Reyes, Kelly A Hu, Jacob Teperman, Theresa L Wampler Muskardin, Jean-Claude Tardif, Binita Shah, Michael H Pillinger

Annals of the Rheumatic Diseases May 2021, 80 (5) 550-557; DOI: 10.1136/annrheumdis-2020-219174
Monocyte and bone marrow macrophage transcriptional phenotypes in systemic juvenile idiopathic arthritis reveal TRIM8 as a mediator of IFN-γ hyper-responsiveness and risk for macrophage activation syndrome
Grant S Schulert, Alex V Pickering, Thuy Do, Sanjeev Dhakal, Ndate Fall, Daniel Schnell, Mario Medvedovic, Nathan Salomonis, Sherry Thornton, Alexei A Grom

Annals of the Rheumatic Diseases May 2021, 80 (5) 617-625; DOI: 10.1136/annrheumdis-2020-217470
Correspondence on ‘Recovery from COVID-19 in a patient with spondyloarthritis treated with TNF-alpha inhibitor etanercept. A report on a patient with COVID-19 with psoriatic arthritis receiving ustekinumab’
Francesco Messina, Francesca Pampaloni, Stefano Piaserico

Annals of the Rheumatic Diseases May 2021, 80 (5) e79; DOI: 10.1136/annrheumdis-2020-218029
JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib
Paqui G Traves, Bernard Murray, Federico Campigotto, René Galien, Amy Meng, Julie A Di Paolo

Annals of the Rheumatic Diseases Mar 2021, annrheumdis-2020-219012; DOI: 10.1136/annrheumdis-2020-219012
Microenvironment in subchondral bone: predominant regulator for the treatment of osteoarthritis
Wenhui Hu, Yueqi Chen, Ce Dou, Shiwu Dong

Annals of the Rheumatic Diseases Apr 2021, 80 (4) 413-422; DOI: 10.1136/annrheumdis-2020-218089
Parsing multiomics landscape of activated synovial fibroblasts highlights drug targets linked to genetic risk of rheumatoid arthritis
Haruka Tsuchiya, Mineto Ota, Shuji Sumitomo, Kazuyoshi Ishigaki, Akari Suzuki, Toyonori Sakata, Yumi Tsuchida, Hiroshi Inui, Jun Hirose, Yuta Kochi, Yuho Kadono, Katsuhiko Shirahige, Sakae Tanaka, Kazuhiko Yamamoto, Keishi Fujio

Annals of the Rheumatic Diseases Apr 2021, 80 (4) 440-450; DOI: 10.1136/annrheumdis-2020-218189
Regulatory eosinophils induce the resolution of experimental arthritis and appear in remission state of human rheumatoid arthritis
Darja Andreev, Mengdan Liu, Katerina Kachler, Mireia Llerins Perez, Philipp Kirchner, Julia Kölle, Andreas Gießl, Simon Rauber, Rui Song, Oliver Aust, Anika Grüneboom, Arnd Kleyer, Juan D Cañete, Arif Ekici, Andreas Ramming, Susetta Finotto, Georg Schett, Aline Bozec

Annals of the Rheumatic Diseases Apr 2021, 80 (4) 451-468; DOI: 10.1136/annrheumdis-2020-218902
TNF is a homoeostatic regulator of distinct epigenetically primed human osteoclast precursors
Cecilia Ansalone, John Cole, Sabarinadh Chilaka, Flavia Sunzini, Shatakshi Sood, Jamie Robertson, Stefan Siebert, Iain B McInnes, Carl S Goodyear

Annals of the Rheumatic Diseases Mar 2021, annrheumdis-2020-219262; DOI: 10.1136/annrheumdis-2020-219262
Response to: ‘Correspondence on ‘Disease activity, cytokines, chemokines and the risk of incident diabetes in rheumatoid arthritis’’ by Ruscitti et al
Joshua F Baker, Bryant R England, Ted R Mikuls

Annals of the Rheumatic Diseases Feb 2021, annrheumdis-2021-220114; DOI: 10.1136/annrheumdis-2021-220114

Main menu

Cytokines

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Cytokines

Pages